ライフサイエンスコーパス: anaplastic lymphoma kinase

1 es the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).

2 portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase).

3 molecular target for the kinase activity of anaplastic lymphoma kinase.

4 expression was not related to expression of anaplastic lymphoma kinase-1.

5 he presence of a translocation involving the anaplastic lymphoma kinase ALK gene.

6 ide 1 was identified as a novel inhibitor of anaplastic lymphoma kinase (ALK enzyme assay IC(50) = 0.

7 Anaplastic lymphoma kinase (ALK) -positive anaplastic la

8 The tyrosine kinase receptor anaplastic lymphoma kinase (ALK) and its ligand, the gro

9 Anaplastic lymphoma kinase (Alk) and leucocyte tyrosine

10 belly (Jeb) and its receptor tyrosine kinase Anaplastic lymphoma kinase (Alk) are localized to develo

11 ncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgro

12 We have recently identified anaplastic lymphoma kinase (ALK) as a tyrosine kinase re

13 recently identified nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) as the genes on chromos

14 The phylogenetic proximity of the ROS1 and anaplastic lymphoma kinase (ALK) catalytic domains led t

15 Abnormal expression of constitutively active anaplastic lymphoma kinase (ALK) chimeric proteins in th

16 essed CD30, epithelial membrane antigen, and anaplastic lymphoma kinase (ALK) consistent with a null

17 Anaplastic lymphoma kinase (ALK) constitutes a part of t

18 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subty

19 We demonstrate that anaplastic lymphoma kinase (Alk) efficiently protects ne

20 lymphoma (ALCL) is a T-cell lymphoma, whose anaplastic lymphoma kinase (ALK) expression varies accor

21 distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression.

22 This review describes the identification of anaplastic lymphoma kinase (ALK) fusion genes in approxi

23 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represe

24 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presume

25 Oncogenic anaplastic lymphoma kinase (ALK) fusion proteins (nucleo

26 Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining event

27 d here to detection of rearrangements in the anaplastic lymphoma kinase (ALK) gene associated with AL

28 ssed nucleophosmin (NPM) gene at 5q35 to the anaplastic lymphoma kinase (ALK) gene at 2p23, which is

29 Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hered

30 The anaplastic lymphoma kinase (ALK) gene fuses to the nucle

31 he discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer.

32 The anaplastic lymphoma kinase (ALK) gene is characteristica

33 as (ALCLs) carry translocations in which the anaplastic lymphoma kinase (ALK) gene is juxtaposed to v

34 normalities of 2p23 and rearrangement of the anaplastic lymphoma kinase (ALK) gene locus.

35 Molecular testing is positive for an anaplastic lymphoma kinase (ALK) gene rearrangement usin

36 Anaplastic lymphoma kinase (ALK) gene rearrangements are

37 In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are

38 dermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements.

39 Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sI

40 Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a

41 Anaplastic lymphoma kinase (Alk) has been proposed to re

42 Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in

43 2 gene, which, we show, encodes the nematode anaplastic lymphoma kinase (ALK) homolog, a proto-oncoge

44 usly shown both humoral and CTL responses to anaplastic lymphoma kinase (ALK) in patients with ALK-po

45 Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimi

46 Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has sh

47 Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type

48 that may rationalize clinical evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this sett

49 lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with differe

50 naene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to

51 Anaplastic lymphoma kinase (ALK) is a promising new targ

52 Anaplastic lymphoma kinase (ALK) is a promising therapeu

53 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

54 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

55 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

56 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

57 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

58 Anaplastic lymphoma kinase (ALK) is a transmembrane rece

59 Here we show that the anaplastic lymphoma kinase (ALK) is aberrantly activated

60 The anaplastic lymphoma kinase (ALK) is chromosomally rearra

61 The orphan receptor anaplastic lymphoma kinase (ALK) is one of very few RTKs

62 Here we show that transcription of anaplastic lymphoma kinase (Alk) is repressed by LMO4 in

63 MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce

64 Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 1

65 ely half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p2

66 Anaplastic lymphoma kinase (ALK) mutations occur in 3% t

67 malignant transformation of T cells that are anaplastic lymphoma kinase (ALK) negative and CD30 posit

68 The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine k

69 The metabolic shift is mediated through the anaplastic lymphoma kinase (ALK) phosphorylation of the

70 , we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed gro

71 The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein expression and

72 hromosomal translocations that juxtapose the anaplastic lymphoma kinase (ALK) proto-oncogene to a dim

73 l fusion gene that incorporates parts of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinas

74 Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinas

75 the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially u

76 Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in ap

77 aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prom

78 sets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations.

79 ormation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are onl

80 h epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

81 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

82 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

83 Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

84 ell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain

85 n protein containing the catalytic domain of anaplastic lymphoma kinase (ALK) under the control of th

86 Anaplastic Lymphoma Kinase (ALK) was originally identifi

87 protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM

88 ;5)(p23;q35) results in the juxtaposition of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM

89 t down-regulation of TIMP1 expression in two anaplastic lymphoma kinase (ALK)(+) ALCL cell lines, Kar

90 vered in many T-cell malignancies, including anaplastic lymphoma kinase (ALK)(-) anaplastic large cel

91 Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface recepto

92 ntained chromosomal translocations involving anaplastic lymphoma kinase (ALK), a novel receptor tyros

93 Jeb receptor is the Drosophila homologue of anaplastic lymphoma kinase (Alk), a receptor tyrosine ki

94 a distinct role for one of the DMGs encoding anaplastic lymphoma kinase (ALK), an important regulator

95 se domain that is physiologically related to anaplastic lymphoma kinase (ALK), and is undergoing Phas

96 EGFR), rearranged during transfection (RET), anaplastic lymphoma kinase (ALK), and MAPK1/3 and other

97 ts in nonsmall cell lung cancer fuse EML4 to anaplastic lymphoma kinase (ALK), causing expression of

98 Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), a

99 otubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an invers

100 Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently show

101 ecently identified receptor tyrosine kinase, anaplastic lymphoma kinase (ALK), in embryonic chick by

102 by R1-R6 axons interacts with its receptor, anaplastic lymphoma kinase (Alk), on budding dendrites t

103 omosome 5q35 to a novel protein kinase gene, Anaplastic Lymphoma Kinase (ALK), on chromosome 2p23.

104 Anaplastic lymphoma kinase (ALK), physiologically expres

105 Anaplastic lymphoma kinase (ALK), physiologically expres

106 e phosphatase receptor zeta (PTPRZ1) and the anaplastic lymphoma kinase (ALK), respectively.

107 MK binds to anaplastic lymphoma kinase (ALK), the receptor for PTN,

108 lating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5

109 ), human epidermal growth factor receptor 2, anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma v

110 A gene residing in this locus, the anaplastic lymphoma kinase (Alk), was expressed at signi

111 YCN cooperates with mutational activation of anaplastic lymphoma kinase (ALK), which promotes progres

112 absence of translocations that activate the anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK

113 ied, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-negative anaplastic lar

114 Anaplastic lymphoma kinase (ALK)-negative anaplastic lar

115 d) and active (underphosphorylated), in four anaplastic lymphoma kinase (ALK)-positive ALCL cell line

116 Anaplastic lymphoma kinase (ALK)-positive anaplastic lar

117 e SHH/GLI1 signaling pathway is activated in anaplastic lymphoma kinase (ALK)-positive anaplastic lar

118 Anaplastic lymphoma kinase (ALK)-positive anaplastic lar

119 ssion was seen in only 1 of 15 patients with anaplastic lymphoma kinase (ALK)-positive anaplastic lar

120 orrelates with relapse risk in children with anaplastic lymphoma kinase (ALK)-positive anaplastic lar

121 a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative,

122 ngioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-neg

123 heterogeneous disease that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALK-negati

124 While most anaplastic lymphoma kinase (ALK)-positive non-Hodgkin ly

125 h crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell

126 oma, small molecule inhibitor crizotinib for anaplastic lymphoma kinase (ALK)-rearranged inflammatory

127 In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer,

128 cacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-ce

129 Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto

130 he dimerization domain of nucleophosmin with anaplastic lymphoma kinase (ALK).

131 express the receptor for this growth factor, anaplastic lymphoma kinase (ALK).

132 (ECD) of the orphan receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

133 smic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

134 2;5)(p23;q35) resulting in overexpression of anaplastic lymphoma kinase (ALK).

135 smic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

136 eloped as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).

137 scaffold will be described for inhibitors of anaplastic lymphoma kinase (ALK).

138 lymphomas characterized by the expression of anaplastic lymphoma kinase (ALK+ TCL) fail to express th

139 leophosmin/B23 (NPM) gene (5q35) and a novel anaplastic lymphoma kinase (ALK; 2p23) are the fused gen

140 or survivin expression in 62 ALCL tumors (30 anaplastic lymphoma kinase [ALK]-positive and 32 ALK-neg

141 to be independent of nuclear localization of anaplastic lymphoma kinase; and phospholipase C-gamma wa

142 2;5) were mapped; constitutive activation of anaplastic lymphoma kinase by a chromosomal inversion wa

143 During the last year the expression of anaplastic lymphoma kinase clarified presentation and pr

144 PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >12

145 noderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is

146 p studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associat

147 xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are de

148 d the resulting fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) are detected in 50%

149 utively active tyrosine kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressing anaplast

150 Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic

151 Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusi

152 ction of the nucleolar protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) protein.

153 mation of the chimeric protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), which possesses si

154 ting in aberrant expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

155 neration of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

156 ;q35) and aberrantly expresses nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

157 oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

158 neration of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

159 The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)/phospholipase C-gam

160 ted by the oncogenic, chimeric nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) tyrosine kinase rem

161 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cel

162 r angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic

163 t this receptor is expressed on T cells from anaplastic lymphoma kinase-positive (ALK(+)) anaplastic

164 Using conditional transgenic models of anaplastic lymphoma kinase-positive (ALK(+)) lymphomas a

165 Anaplastic lymphoma kinase-positive (ALK+) ALCL is assoc

166 sociated T-cell lymphoma patients (excluding anaplastic lymphoma kinase-positive anaplastic large cel

167 Anaplastic lymphoma kinase-positive anaplastic large-cel

168 d in a caspase-dependent manner in apoptotic anaplastic lymphoma kinase-positive, anaplastic large ce

169 accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic

170 clude the possibility of an EGFR mutation or anaplastic lymphoma kinase translocation or to identify

171 assively parallel sequencing instrument, and anaplastic lymphoma kinase translocation was evaluated b

172 vity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors ha